Bimzelx (bimekizumab-bkzx) — Medica

Psoriatic arthritis

Initial criteria

Patient is age ≥ 18 years
According to the prescriber, the patient has been evaluated for risks of suicidal ideation or behavior versus benefits of therapy
According to the prescriber, the patient does not have moderately severe to severe depression
According to the prescriber, within the past 5 years, the patient does not have a history of suicidal ideation or suicidal behavior
The medication is prescribed by or in consultation with a rheumatologist or a dermatologist

Patient has been established on therapy for at least 6 months
According to the prescriber, the patient has been evaluated for risks of suicidal ideation or behavior versus benefits of therapy
According to the prescriber, the patient does not have moderately severe to severe depression
According to the prescriber, the patient does not have suicidal ideation or suicidal behavior
Patient meets at least one of the following: (a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating Bimzelx); OR (b) Compared with baseline, patient experienced an improvement in at least one symptom, such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths

initial 6 months, reauthorization 1 year